Premier Partners is a private equity firm based in Seoul, South Korea, established in September 2005. The company specializes in managing domestic investment funds and offers investment services to both individuals and businesses. Premier Partners focuses on a diverse range of sectors, including bio, life science, healthcare, mobility, industrials, mobile, brand and e-commerce, as well as digital content. Through its targeted investment approach, the firm aims to support and grow companies within these industries.
Medisol is a food technology firm that also provides personalized food care solutions.
Prazer Therapeutics
Series B in 2025
Prazer Therapeutics is a biotechnology company dedicated to developing novel therapeutics for patients suffering from intractable diseases, particularly focusing on neurodegenerative and refractory inflammatory conditions. The company employs innovative drug design approaches, including rational molecular drug design and next-generation protein degradation technology, to create effective treatments. By leveraging these advanced platforms, Prazer Therapeutics aims to address significant unmet medical needs and enhance the treatment landscape for challenging health issues.
Healing Paper
Series C in 2025
Healing Paper operates a platform focused on enhancing access to cosmetic surgery services while promoting transparency and affordability. The company utilizes information and communication technology to provide patients with estimates for necessary procedures, honest reviews, and special pricing options. In addition to connecting patients with cosmetic treatment options, Healing Paper fosters a real-time community for sharing experiences and offers management tools for post-surgery care. By balancing information between medical professionals and patients, Healing Paper aims to improve the quality of cosmetic beauty services and make them more accessible.
Gangnam Unni
Series C in 2025
Gangnam Unni is in the field of beauty medical services, helping users choose a treatment and a plastic surgery hospital. The difficulty of navigating the process of seeking medical treatment and choosing a hospital continues to persist. Kangnam Unni recognizes the need for change and firmly believes that a combination of transparent medical information and an IT platform can foster a consumer-oriented medical service market. Their ultimate goal is to challenge negative perceptions surrounding plastic surgery and spearhead a significant transformation in the beauty and medical service industries. The Gangnam Unni team is dedicated to innovation, fueled by an unwavering desire to provide exceptional beauty and medical services. With the aim of assisting individuals in selecting a suitable hospital, they have amassed an impressive database of one million user reviews. Additionally, their efforts to promote transparency in medical information have garnered the support of 3,000 subscribers through Gangnam Sister. Furthermore, their mobile application has facilitated hospital consultations for a staggering 3.8 million individuals, resulting in 1.6 million successful cases. As the team continuously clarifies its mission and forges ahead with determination, its collective strength and resolve only grow stronger. Kangnam Unni remains committed to revolutionizing the healthcare industry, ensuring that individuals receive the highest quality of care and a positive experience throughout their medical journeys.
Microbiotix
Series B in 2024
MicrobiotiX specializes in developing therapeutics that leverage bacteriophages and the microbiome to address multidrug-resistant infections and autoimmune diseases. The company has created a platform that facilitates the use of safe gastrointestinal microbiota transplants, enabling the formulation of fecal microbiota transplant capsules for oral administration. This innovative approach allows for convenient and cost-effective treatment options for patients, while also focusing on the research and development of bacteriophages. By integrating these technologies, MicrobiotiX aims to improve healthcare outcomes and combat pressing medical challenges.
Aigen Sciences
Series A in 2024
AIGEN Sciences is an AI-driven drug discovery platform that focuses on providing research and development services for pharmaceutical innovations. The company specializes in discovering high-potency drugs that target specific cellular activities while minimizing off-target effects and toxicity. This approach allows AIGEN Sciences to facilitate the rapid development of effective medications at a lower cost, ultimately benefiting clients in the pharmaceutical industry.
Lucas
Series B in 2024
Lucas develops a system to detect, measure, categorize and track nodules in the screening CT images.
Superb AI
Series C in 2024
Superb AI is a comprehensive training data platform that automates data preparation, facilitating rapid and systematic dataset creation and management. Founded in 2018 by a team of data scientists, academics, and machine learning engineers, the company focuses on transforming how organizations label, manage, curate, and deliver training data. With a strong foundation in computer vision and deep learning, supported by extensive academic research and numerous publications, Superb AI enables businesses to streamline their AI projects. The platform includes features for data annotation, curation, model training, and deployment, allowing companies to develop and implement computer vision applications more efficiently.
Upstage
Series B in 2024
Upstage AI is a startup that specializes in providing customized artificial intelligence services to businesses. The company develops tailored AI models designed to address specific challenges faced by its clients, thereby enhancing operational efficiency and fostering innovation. By enabling organizations to focus on their core tasks, Upstage AI helps them leverage AI technology to solve problems and advance their business processes effectively.
AITRICS
Series B in 2024
AITRICS is focused on enhancing patient outcomes through a clinical decision support platform that leverages health data effectively. By utilizing machine learning technologies combined with evidence-based expert analysis, the platform provides real-time clinical insights aimed at transforming traditional reactive disease management into a more proactive, preventive, personalized, and participatory approach to healthcare. This innovative solution is designed to empower clinicians by enhancing treatment strategies and expanding their knowledge, ultimately facilitating better health management for patients. AITRICS comprises a dedicated team of professionals from diverse backgrounds, united by a shared vision to make data-driven health intelligence accessible to all.
Bertis
Venture Round in 2024
Bertis Inc. is a proteomics-based molecular diagnostics company focused on developing and commercializing cancer-related biomarkers for early disease detection. Founded in 2014 and based in Seongnam, South Korea, the company offers Mastocheck, a screening method for diagnosing stage 1 breast cancer. Bertis is engaged in extensive research for biomarker development aimed at the early diagnosis of various carcinomas, as well as the creation of new therapeutic markers and co-markers. Utilizing advanced bio-big data analysis technologies, the company seeks to uncover biomarkers across multiple fields by integrating proteomics, genomics, and bioinformatics. Additionally, Bertis is developing an AI-based diagnostic platform to enhance the diagnosis of cancer and cardiac diseases, thereby enabling more effective early detection and treatment options for medical practitioners.
Nventric
Series B in 2024
Nventric is a medical device company focused on developing innovative solutions for neurovascular, coronary heart, and peripheral vascular applications. The company's primary product is designed to remove blood clots that lead to ischemic strokes. This device utilizes a stent retriever that can be inserted into the artery in the leg, allowing physicians to effectively access and remove blood clots responsible for arterial occlusion. By enhancing the treatment process for ischemic stroke, Nventric aims to improve patient outcomes and advance medical care in vascular conditions.
Kanaph Therapeutics
Series C in 2023
Kanaph Therapeutics Inc. is a biotechnology company focused on drug development, from discovery to early-stage clinical trials, primarily targeting oncology and autoimmune diseases. Founded in 2019 and headquartered in Seoul, South Korea, the company specializes in creating next-generation therapeutics, including bi-specific antibodies, Fc-fusions, and small molecules. Its oncology pipeline aims to improve immuno-stimulatory activity within the tumor microenvironment to enhance patient response rates for immuno-oncology treatments. Additionally, Kanaph Therapeutics develops therapeutic solutions for autoimmune conditions, utilizing bispecific Fc-fusions that inhibit pathways associated with complement activation and angiogenesis. The company operates in both Korea and the United States, striving to provide innovative treatments for complex diseases.
Medipixel
Series B in 2023
Medipixel, Inc., founded in 2017 and based in Seoul, South Korea, specializes in developing artificial intelligence-based diagnostic software and semi-autonomous surgical tools for lung cancer and cardiac disease interventions. The company employs a team of experts in computer vision, deep learning, and reinforcement learning, collaborating with leading healthcare institutions to enhance diagnostic and surgical processes. Medipixel offers several innovative solutions, including an AI-based diagnosis tool that assists doctors in identifying lesions during coronary angiography, a guide and planning solution that visualizes hidden coronary artery segments to facilitate guidewire manipulation, and an automated navigation engine that optimizes robotic control for surgical procedures. By integrating advanced AI technologies, Medipixel aims to improve the quality of medical care and patient outcomes in the field of surgery.
Moloco
Series D in 2023
Moloco Inc., founded in 2013 and based in Palo Alto, California, specializes in programmatic advertising solutions aimed at optimizing client acquisition, retention, and monetization strategies. The company offers a cloud-based demand-side platform that leverages machine learning to help businesses of all sizes enhance user acquisition and maximize lifetime value through predictive models. Additionally, Moloco provides a mobile e-commerce platform that supports targeted re-engagement campaigns, allowing application publishers and e-commerce platforms to expand their customer reach more effectively than traditional advertising methods. With a team comprised of top talents from leading tech firms, Moloco is committed to empowering mobile businesses to thrive in a competitive landscape.
MangoBoost
Series A in 2023
MangoBoost specializes in advanced system solutions aimed at enhancing AI data center efficiency. The company's flagship product, the MangoBoost DPU, is designed to optimize AI infrastructure by ensuring compatibility with various GPUs, accelerators, and storage products. This solution effectively utilizes legacy infrastructure while providing a user-friendly network system. Founded in 2022, MangoBoost leverages a decade of prior research recognized at leading conferences, and its team comprises over 80 professionals, including system architects, software engineers, and FPGA/SoC engineers, many of whom possess PhDs from prestigious institutions and significant experience in the tech industry. The company has raised over 60 million dollars in funding and is actively expanding its operations in the United States, Canada, and South Korea.
EverEx
Series A in 2023
EverEx is a software-based therapeutics company specialized on musculoskeletal disorders with an AI-enabled pose estimation.
VCAT.AI
Series A in 2023
VCAT.AI is a business-to-business (B2B) subscription software (SaaS) based on AI technology. Create mass marketing creatives as video and banner images just with an product URL or TEXT.
Pion
Series A in 2023
Pion Corporation is a marketing technology company specializing in video intelligence. It offers "Vispot," an AI-driven platform for video creation and ad automation. This application is designed to assist video creatives by providing automated services for video production and optimization. By leveraging artificial intelligence, Pion enables businesses to enhance their marketing capabilities and streamline the video advertising process.
Ideahub
Venture Round in 2023
Ideahub Inc. is a professional services company specializing in patent monetization and intellectual property (IP) licensing and commercialization. Founded in 2016 and headquartered in Seoul, South Korea, Ideahub offers an IP licensing platform designed to help clients monetize their IP portfolios. The company provides a range of services, including licensing support and potential revenue analysis, focusing on various sectors such as the Internet of Things (IoT), industrial automation, telecommunications, audio technology, augmented and virtual reality, and video entertainment.
Toss Bank
Venture Round in 2023
Toss Bank is an internet banking services company in South Korea that aims to innovate the financial landscape by focusing on customer-centered banking solutions. As a challenger bank, it seeks to address the needs of both retail and commercial clients, particularly targeting economically disadvantaged individuals who have been marginalized by traditional financial systems. Toss Bank provides a range of services including interest-bearing accounts, various deposit and withdrawal options, and streamlined loan processes. Additionally, it offers wealth management, currency exchange, and secure deposit services, all designed to enhance accessibility and convenience for its customers.
Yipscell
Series B in 2022
Yipscell is a biotech company that develops IPSC stem cell therapy to diagnose and treat incurable diseases.
Onconic Therapeutics
Series B in 2022
Onconic Therapeutics is dedicated to the research and development of innovative cancer treatments. The company focuses on creating next-generation anti-cancer therapies that target the mechanisms involved in cancer cell growth and DNA damage repair. By simultaneously suppressing key signal delivery agents and repair enzymes, Onconic aims to provide healthcare professionals with effective therapeutic options for treating various cancers.
LINE Studio
Private Equity Round in 2022
LINE Studio is a casual game developer associated with a global messaging platform. The company focuses on creating mobile games intended for the e-gaming sector, researching and developing titles across various genres. By prioritizing user engagement, LINE Studio aims to enhance leisure time for players, offering enjoyable and accessible gaming experiences.
EverEx
Funding Round in 2022
EverEx is a software-based therapeutics company specialized on musculoskeletal disorders with an AI-enabled pose estimation.
Codit
Seed Round in 2022
CODIT is a company focused on simplifying access to government data, enabling businesses to stay informed about legal and regulatory changes that may affect their operations. The firm has created a data-monitoring platform that allows clients to efficiently track and analyze significant updates in local legislation, regulations, and policies. By utilizing artificial intelligence, CODIT consolidates information from numerous government and ministerial sites into a user-friendly database, streamlining the research process for Policy Managers. The platform also distills lengthy documents into concise, easily understandable summaries. With an expanding user base and increasing media attention, CODIT aims to establish itself as a primary information hub in South Korea, Singapore, and the United States, supporting organizations in their engagement with government stakeholders and enhancing their understanding of government affairs.
Dudum
Seed Round in 2022
Dudum is a video production company that specializes in connecting brands with video editors through its platform. The company offers a range of services, including graphics, product advertisements, and in-house training. Its platform allows businesses to receive quotes from video-making professionals and features a custom search option, enabling users to find various types of video content tailored to their specific needs. By facilitating the creation of video campaigns, Dudum supports brands in enhancing their visual marketing efforts.
Superb AI
Series B in 2022
Superb AI is a comprehensive training data platform that automates data preparation, facilitating rapid and systematic dataset creation and management. Founded in 2018 by a team of data scientists, academics, and machine learning engineers, the company focuses on transforming how organizations label, manage, curate, and deliver training data. With a strong foundation in computer vision and deep learning, supported by extensive academic research and numerous publications, Superb AI enables businesses to streamline their AI projects. The platform includes features for data annotation, curation, model training, and deployment, allowing companies to develop and implement computer vision applications more efficiently.
SK Ecoplant
Venture Round in 2022
SK Ecoplant is a prominent global city developer and infrastructure builder, recognized as a leading subsidiary of SK Group. The company specializes in engineering projects on an EPCC (Engineering, Procurement, Construction, and Commissioning) basis, focusing on sectors such as refineries, petrochemicals, fertilizers, industrial plants, and environmental facilities. It has established a strong presence in the high-tech engineering market, with significant projects underway across various countries, including the U.S., Saudi Arabia, China, and more. SK Ecoplant is also committed to sustainability, integrating green practices into its operations to support economic growth and industrial development in Korea and beyond. By leveraging extensive project experience and advanced technology, the company aims to enhance its internal processes and expand its reach in overseas markets, positioning itself for future growth.
Boostimmune
Venture Round in 2022
Boostimmune is a biotechnology company focused on developing antibody-based therapies to address unmet needs in oncology by enhancing the immune response against cancer. The company is dedicated to researching and developing innovative immuno-oncology drugs that target myeloid-derived suppressor cells (MDSCs), which are known to inhibit the immune system's ability to combat cancer cells. By modulating these immune suppressor cells, Boostimmune aims to increase the activity and frequency of T cells, ultimately improving the body's capacity to eliminate tumors. The team at Boostimmune is composed of industry experts committed to overcoming the challenges of cancer treatment and advancing novel anti-cancer therapies.
Absology
Series B in 2022
Absology is a developer of in-vitro diagnostic systems aimed at enhancing patient care and saving lives. The company provides a range of diagnostic kits, including those for testosterone, vitamin D, PSA, TSH, FreeT4, and PCT. Additionally, Absology's platform supports monitoring for anti-cancer therapies, cardiovascular diseases, and Alzheimer's disease, thereby facilitating accurate diagnosis and effective treatment of various medical conditions. Through its innovative solutions, Absology enables healthcare professionals to make informed decisions that improve patient outcomes.
Xangle
Series B in 2022
Xangle operates a platform that consolidates and standardizes corporate disclosures related to crypto assets. The company collects, verifies, and integrates information from global projects and companies that have issued digital assets, making this data publicly accessible. By providing both on-chain metrics and off-chain corporate disclosures, Xangle addresses the challenges associated with analyzing raw blockchain data, thereby enhancing public understanding of crypto assets. The platform aims to facilitate the intrinsic valuation of projects by collaborating with token projects, exchanges, and investors, promoting secure and institutionalized public data disclosure practices.
IVIM Technology
Series C in 2022
IVIM Technology, Inc. specializes in the development and manufacture of advanced IntraVital Microscopy platforms and related medical devices. Based in Daejeon, South Korea, the company was founded in 2017 and focuses on live cell intravital imaging, which allows for the monitoring of drug efficacy and delivery in real-time within living organisms. Its technology enables the analysis of cellular interactions and the complex processes underlying human diseases, particularly in the context of new biopharmaceuticals, including immunological, cell, gene, and antibody therapies. IVIM Technology's services include whole tissue 3D imaging, providing comprehensive insights into drug performance at the cellular level.
M83
Venture Round in 2022
M83 is a media studio that specializes in the production of movies and television series utilizing computer graphics and visual effects technology. The company supports directors by providing advanced CG and VFX capabilities, enabling the creation of visually compelling content. M83 is actively involved in the media industry, focusing on delivering high-quality video content across various genres.
Genecker
Venture Round in 2022
Genecker is a cancer diagnosis and testing center that specializes in genetic analysis services. The company offers a range of testing options, including cancer genomes, prenatal genomes, rare disease genomes, and individual genomes. By focusing on personalized diagnostics and treatment, Genecker aims to enhance health care methods for its customers. The organization is committed to delivering quality diagnosis technology at competitive prices, ultimately promoting a healthier life and well-being for individuals.
KaliVir Immunotherapeutics
Series A in 2022
KaliVir Immunotherapeutics focuses on developing innovative oncolytic viral immunotherapy products aimed at treating various tumor types. The company utilizes a novel oncolytic vaccinia platform to enhance the systemic delivery of therapies through intravenous methods, ensuring targeted replication and effective viral spread within tumors. Their programs incorporate both in-house technologies and licensed advancements from the University of Pittsburgh, a leader in oncolytic virus and immunotherapy research. By leveraging proprietary genetic modifications, KaliVir aims to provide healthcare professionals with advanced treatment options that harness the body's immune response to combat cancer effectively.
Jobis
Venture Round in 2022
Jobis is an accounting management platform by AI.
Clodot
Series B in 2022
Clodot is an information technology company.
Law&Company
Series C in 2022
Law&Company is representative legal tech company in Republic of Korea. The company provides a service called 'LawTalk(www.lawtalk.co.kr)', which is the largest online legal market place in Korea(5 times bigger then the 2nd player). Since 2016, the company invested on research about Artificial Intelligence especially on Text Mining and Machine Learning technology to analyze lawyers and client's activities in the service which helps to lawyers and clients find the right person based on their experience. Also, the company will launch document automation based service to generate legal documents starting from complaint and contract soon. The company has received more than 3 million dollars from 5 venture capital companies and many angel investors due to previous performance and upside potential in the Korean legal market.
Immuneoncia Therapeutics
Secondary Market in 2022
ImmuneOncia Therapeutics Inc. is a biopharmaceutical company focused on developing anti-cancer drugs, particularly in the field of immuno-oncology. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company is headquartered in Yongin-Si, South Korea. ImmuneOncia's primary product is IMC-001, a monoclonal antibody currently undergoing Phase 1 clinical trials, aimed at treating various types of cancer. The company combines the drug development and antibody engineering expertise of its parent organizations to create safe and effective immunotherapies for oncology patients worldwide.
Lucas
Series A in 2021
Lucas develops a system to detect, measure, categorize and track nodules in the screening CT images.
Unlimeat
Venture Round in 2021
Unlimeat is a company specializing in the production of plant-based meat products that serve as sustainable and environmentally friendly food substitutes. Its offerings include a variety of items such as sliced meat, minced meat, burger patties, and pulled barbecue, all designed to replicate the texture, flavor, and aroma of traditional meat. Unlimeat focuses on utilizing perfectly edible but cosmetically imperfect produce that would otherwise go to waste, aligning with its commitment to sustainability. The company's plant-based meats are versatile, making them suitable for both Eastern and Western culinary applications. As a member of the Upcycled Food Association, Unlimeat emphasizes its dedication to reducing food waste while providing conscientious consumers with eco-friendly alternatives to conventional meat.
Breezytail
Series A in 2021
Breezytail is a pet service company that specializes in pet lifestyle products, focusing on enhancing pet health care. The company provides a diverse range of offerings, including face care, hair care, and bath products, as well as household goods designed for pets. By prioritizing the well-being of pets, Breezytail aims to help them live longer and healthier lives through its carefully developed product line.
Upstage
Series A in 2021
Upstage AI is a startup that specializes in providing customized artificial intelligence services to businesses. The company develops tailored AI models designed to address specific challenges faced by its clients, thereby enhancing operational efficiency and fostering innovation. By enabling organizations to focus on their core tasks, Upstage AI helps them leverage AI technology to solve problems and advance their business processes effectively.
Munpia
Venture Round in 2021
Munpia Inc. is an online media company based in Seoul, South Korea, established in 2012. It specializes in publishing online news and a database, with a focus on events news and web novels. The company primarily caters to adult readers, offering a platform for writers and readers to engage in the creation and enjoyment of web novels, particularly in the martial arts genre. By enabling participation from both writers and readers, Munpia fosters a collaborative environment for fantasy storytelling.
Aardvark Therapeutics
Series B in 2021
Aardvark Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing and commercializing small molecule therapeutics for obesity and rare genetic metabolic disorders. Founded in 2017 by Tien Lee, the company has introduced Bittera, a first-in-class oral composition designed to selectively disrupt hunger signaling and regulate energy homeostasis. This innovative therapeutic approach provides clinicians with an effective and safe treatment option for obesity-related diseases, without interfering with nutrient absorption. Aardvark Therapeutics aims to address significant health challenges associated with obesity and metabolic conditions through its specialized drug development efforts.
Karis Bio
Series A in 2021
Karis Bio focuses on the development of innovative cell therapies aimed at treating cardiovascular diseases. The company utilizes patented technology that involves the generation of induced pluripotent stem cells (iPSCs) and their differentiation into endothelial cells. This approach is designed to provide effective treatments for patients suffering from cardiovascular conditions, enhancing their recovery and overall health.
April Bio
Series C in 2021
April Bio is a drug development company that develops antibodies and long-acting biologics.
Jeongyookgak
Series C in 2021
Jeongyookgak is a company that specializes in the production and sale of fresh meat and groceries. It offers a variety of food items, including pork, beef, eggs, and grass-fed meat, catering to customers seeking high-quality and healthy food options. The company emphasizes rapid delivery services, ensuring that customers receive their orders promptly. By providing online assistance for food delivery, Jeongyookgak aims to meet the growing demand for convenient access to fresh food at reasonable prices.
Publy
Series B in 2021
PUBLY is an online content platform tailored for working individuals, offering subscription services that facilitate access to curated content. The platform specializes in creating, designing, archiving, and publishing custom content and events, which users can reserve for future reference. This enables users to purchase and publish content from various media sources, providing a convenient way to access and manage relevant information. By focusing on the needs of professionals, PUBLY aims to enhance the content consumption experience for its users.
Mega MGC Coffee
Venture Round in 2021
Mega MGC Coffee is a specialty store that offers a delightful range of beverages and robust coffee made from 100% Arabica beans. As the prices of coffee continue to rise, consumers are increasingly inclined towards low-cost coffee options. The escalating coffee prices have prompted people to actively seek out more affordable alternatives. Mega MGC Coffee, a budget-friendly coffee franchise, has garnered substantial attention in this context. As of January 5, 2023, the franchise had successfully established a cumulative total of 2,212 stores and consistently announced new store openings.
Reebonz Korea
Series A in 2021
Reebonz Korea, Ltd is a company based in Seoul, South Korea, specializing in the import, export, wholesale, and retail of luxury products for both men and women. The company provides a wide range of items, including bags, wallets, watches, shoes, clothing, cosmetics, and fashion accessories. Reebonz operates an e-commerce marketplace that features popular luxury goods as well as pre-owned items from coveted designer brands. The platform offers customers the convenience of shopping for the latest fashion items and includes options for both buying and selling, along with personalized services.
Barogo
Series C in 2021
Barogo provides a last-mile delivery platform to clients in order to generate new and creative business opportunities. It focuses on the ecosystem of connectivity and connects all possible businesses and customers. It was founded in 2014 and is based in Seoul, South Korea.
Hince
Series B in 2021
Hince is a brand that specializes in offering a diverse range of personal care products, including skin, lip, eye, and face care items. The company focuses on developing mood narrative makeup products, such as lipsticks, compacts, eye shadows, and lip glosses. Hince emphasizes the use of natural and vegan ingredients in its cosmetics, appealing to consumers who seek environmentally friendly and ethically produced beauty products. By providing a wide selection of high-quality items, Hince aims to enhance individual beauty while promoting a healthier approach to makeup.
Yipscell
Series A in 2021
Yipscell is a biotech company that develops IPSC stem cell therapy to diagnose and treat incurable diseases.
Iksuda Therapeutics
Series A in 2021
Iksuda Therapeutics is a biotechnology company focused on developing innovative biotherapeutics aimed at treating challenging cancers, particularly those that are resistant to existing therapies. The company specializes in antibody-drug conjugates, which are designed to target specific tumor types through a strategic combination of payloads, linkers, and conjugation chemistry. This targeted approach enhances the efficacy of cancer treatments, providing patients with new therapeutic options for difficult-to-treat tumors.
Stars Tech
Venture Round in 2021
Traditional de-icers such as salt and calcium chloride are effective, but they also cause economic, health and environmental harms such as iron corrosion, concrete damage, plant sulfurization and respiratory problems. To solve this problem, STAR'S TECH developed and commercialized the world's first eco-friendly de-icing agent using starfish extract. This unique solution provides superior results when compared with other traditional de-icing methods. ECO-ST1 is an eco-friendly de-icing agent made from sea waste starfish. It is developed by researchers at Seoul National University and helps reduce the overhead costs of deicing by up to 90%. 80% of the cost of de-icing is overhead. ECO-ST1 prevents traffic accidents through rapid and continuous melting and minimizes iron corrosion and concrete damage to minimize the cost of repairing roads, bridges, vehicles, and guard rails. It also solves road damage by minimizing plant sulfurization. STAR'S TECH has developed an innovative technology to extract the porous structures from starfish. Unstable chloride ions resulting from deicing are absorbed by these porous structures through electrostatic force. Starfish extract helps control chloride ion concentration, which can otherwise be detrimental to the environment. This technology also enables corrosion inhibitor reaction by using very few anti-corrosion agents. ECO-ST1 is manufactured in a bead form rather than the commonly used flake form. This bead is coated with starfish extract and a diffuser for de-icing. Beads are advantageous because they have greater penetration and de-icing performance. Also, as this starfish-coated bead does not create dust, it does not cause respiratory problems.
Yunsung F&C
Venture Round in 2021
Yunsung F&C focus on the Engineering, Procurement, and Construction business. Yunsung F&C has played a significant role in the advancement of industries such as biopharmaceuticals, rechargeable batteries, and food. With its accumulated technology and expertise, Yunsung F&C focuses on EPC (Engineering, Procurement, and Construction) projects that encompass the entire process, from design and engineering to procurement, production, installation of equipment and materials, piping and electrical works, and the automatic control system. As a total solution partner, the company works hand in hand with its customers, utilizing its technical capabilities and know-how. Yunsung F&C is dedicated to contributing to the plant industry in Korea and expanding its reach as a global company, driven by its commitment to world-class quality and technology. The company also strives for sustainable quality innovation, customer satisfaction management, and the provision of superior products and services, aiming for mutual growth and prosperity alongside its valued customers.
Ably
Series B in 2021
Ably Corporation operates a fashion platform that enables customers to buy and sell products among themselves. The platform features a forum where influencers and celebrities can establish online stores to showcase and sell their products. This model allows users to stay informed about the latest fashion trends and purchase clothing items similar to those worn by their favorite public figures. Ably aims to create a community-driven marketplace that connects consumers with the fashion choices of influential personalities.
Orum Therapeutics
Venture Round in 2021
Orum Therapeutics is a private biotechnology company based in Daejeon, South Korea, founded in 2016. The company specializes in the research and development of therapeutic antibodies through its innovative cell-penetrating antibody platform, Oromab™. This platform is designed to target cytosolic proteins, addressing unmet medical needs in cancer and rare genetic diseases. Orum's unique approach allows for the intracellular delivery of active antibody therapeutics or payloads, enabling the inhibition of drug targets that have been previously considered undruggable by conventional small molecules or antibody therapies. Orum's technology is adaptable to various cell types and intracellular proteins without requiring chemical modifications, aiming to develop effective treatments with improved specificity and reduced toxicity.
Mustbio
Venture Round in 2021
MustBio is a biotechnology company based in Seoul, South Korea, founded in 2021. The company focuses on developing therapeutics for cancer treatment, specifically in the field of immuno-oncology. Utilizing a multi-antibody technology, MustBio creates drugs that mimic a natural asymmetric IgG form, which allows for a high rate of double antibody formation. This innovative approach not only enhances the effectiveness of the treatments but also offers economic feasibility, making it possible for healthcare companies to provide effective therapies for a range of cancer types.
Kmong
Series C in 2021
Kmong Inc. is a South Korean company that operates a freelance and micro-job marketplace, facilitating the exchange of services between individuals. Established in June 2012, the platform allows users to buy and sell a wide range of services across various categories, including design, IT and programming, marketing, consulting, translation, writing, and more. Freelancers can list their services with price quotes, making it easier for potential clients to find and engage with them. Kmong's services extend beyond traditional categories to include offerings like private lessons and unique personal services. The company is based in Seoul and provides a mobile application for Android devices, enhancing accessibility for users.
HOWSER
Series B in 2021
HOWSER provides furniture construction and delivery solutions through an online infrastructure based on IT technology.
Gbike
Series B in 2021
Gbike is a mobility sharing startup in Korea, innovating green urban mobility in Korea where currently car-centric environment. Our service includes bike and scooter sharing with IT services specialized for Korean market & Asia, Pacifics.
HealthHub
Venture Round in 2021
Healthhub is a healthcare professional company that specializes in developing cloud-based scientific image software aimed at enhancing medical interpretation. The platform integrates user interface and user experience design with input from radiologists, creating an optimized environment for personalized results. It facilitates real-time medical image exchange through a web-based suite, allowing hospitals to implement automatic remote solutions effectively. This innovative approach supports improved diagnostic capabilities and streamlines communication within healthcare settings.
PlayList
Series B in 2021
PlayList is a web drama production company that produces dramas and music content. The company's two flagship web drama series, Love Playlist and A-Teen have gained huge popularity amongst the 18-24 age segment. Playlist dramas have over 10 million subscribers and 1.3 billion views.
House Decoration
Series B in 2021
House Decoration is a seller of home interiors, furniture, and home products.
Cookat
Venture Round in 2021
Cookat is a digital content creator focused on food and culinary trends, delivering engaging videos and recipes through various channels. The platform is optimized for mobile users, allowing it to effectively share food-related content on social media. Cookat aims to inspire and inform its audience about unique recipes and gourmet trends while facilitating the purchase of wholesale items, such as restaurant advertisements and home meal replacements, enabling consumers to connect and share with others. Through its innovative approach, Cookat endeavors to enhance the culinary experience for food enthusiasts.
Onegene Biotechnology
Series A in 2021
Onegene Biotechnology is a biotechnology company focused on developing innovative protein-based therapeutics aimed at treating cancer, metabolic, and inflammatory diseases. The company utilizes advanced protein conjugation technology, which involves the connection of separate proteins to create recombinant proteins through post-translational fusion. This approach enables the production of complex proteins with large molecular weights, facilitating the development of multispecific drugs that target multiple pathways simultaneously. Onegene's unique ability to combine various molecular types, including Fab fragments, scFv, sdAb, peptides, cytokines, and enzymes, allows for unprecedented design flexibility and optimized physical properties. Consequently, this innovation expands the potential for effective treatments for complex and multifactorial diseases, offering prolonged benefits for patients.
Superb AI
Series A in 2021
Superb AI is a comprehensive training data platform that automates data preparation, facilitating rapid and systematic dataset creation and management. Founded in 2018 by a team of data scientists, academics, and machine learning engineers, the company focuses on transforming how organizations label, manage, curate, and deliver training data. With a strong foundation in computer vision and deep learning, supported by extensive academic research and numerous publications, Superb AI enables businesses to streamline their AI projects. The platform includes features for data annotation, curation, model training, and deployment, allowing companies to develop and implement computer vision applications more efficiently.
Jobis
Venture Round in 2021
Jobis is an accounting management platform by AI.
Bertis
Venture Round in 2020
Bertis Inc. is a proteomics-based molecular diagnostics company focused on developing and commercializing cancer-related biomarkers for early disease detection. Founded in 2014 and based in Seongnam, South Korea, the company offers Mastocheck, a screening method for diagnosing stage 1 breast cancer. Bertis is engaged in extensive research for biomarker development aimed at the early diagnosis of various carcinomas, as well as the creation of new therapeutic markers and co-markers. Utilizing advanced bio-big data analysis technologies, the company seeks to uncover biomarkers across multiple fields by integrating proteomics, genomics, and bioinformatics. Additionally, Bertis is developing an AI-based diagnostic platform to enhance the diagnosis of cancer and cardiac diseases, thereby enabling more effective early detection and treatment options for medical practitioners.
LUNASOFT
Series B in 2020
LUNASOFT INC. is a South Korean company founded in 2016, specializing in the development of chatbots and integrated management platforms aimed at enhancing customer support. The company offers a range of solutions, including Luna Plus, a courier exchange platform; Luna Plus Mobile, which facilitates real-time business consultations; and Luna Plus CTI, a customer counseling platform that combines phone and intelligent chat counseling. Additionally, LUNASOFT develops customer consultation chatbots tailored for popular messaging platforms such as Naver and Kakao, primarily catering to e-commerce businesses. Based in Seoul, LUNASOFT is focused on providing innovative chat solutions to improve customer interaction and support processes.
Chatie
Venture Round in 2020
Chatie is a chat service software that specializes in a story-writing application aimed at enabling users to create and share narratives in a message format. The application supports various genres, including romantic, horror, and fanfiction, and allows for storytelling through text, video, photos, and sound, as well as offering optional endings. This versatility helps writers engage their audience effectively by presenting stories in a familiar and accessible format.
Vastera
Venture Round in 2020
Bastera is a biotech company with the primary goal of developing groundbreaking treatments for cardiovascular and cancer diseases. Their approach involves targeting new redox signaling pathways, aiming to pioneer "first-in-class" therapies in these fields. Vastera was established in 2018 when SangWon Kang, a professor at Ewha Womans University, transferred a patent based on research results on redox signaling in blood vessels and cancer.
3ProTV
Venture Round in 2020
3ProTV leads the way in disseminating financial knowledge with valuable and comprehensive economic and financial content, playing a prominent role in the industry. 3ProTV is an economic radio station that provides a distinctive depth of content. For those who find the economy perplexing due to numbers and graphs, they strive to simplify and clarify economic concepts using captivating stories and relatable analogies.
Fitpet
Series B in 2020
Fitpet is a developer of a veterinary application aimed at enhancing the quality of life for companion animals and their caregivers. The application utilizes technological advancements to monitor a pet's health status in real time through a comprehensive analysis of various parameters. This enables pet owners to better understand and manage their pets' health needs effectively. Fitpet's mission is to foster a sustainable and wholesome society for pets worldwide.
SK Innovation
Venture Round in 2020
SK Innovation Co., Ltd. is a global energy and chemical company headquartered in Seoul, South Korea. Established in 1962, it operates through four main segments: Petroleum, Petrochemicals, Lubricants, and Others. The company is involved in the exploration, development, and production of crude oil and natural gas, with operations in countries such as the United States, Peru, Vietnam, and China. SK Innovation refines petroleum products, including gasoline, diesel, and aviation fuel, which it supplies to distributors, gas stations, and consumers. Additionally, the company produces a wide range of petrochemical products, such as olefins, synthetic resins, and lubricants, as well as high-capacity lithium-ion batteries for electric vehicles. Beyond its core operations, SK Innovation also provides various services, including insurance and business consulting, and operates a professional football club. With a commitment to innovation, the company has expanded its footprint in both traditional and future energy sectors.
Saige Research
Series A in 2020
Saige Research is a company that focuses on providing artificial intelligence solutions specifically for the manufacturing sector, particularly in the area of industrial inspection and quality control. The firm has developed a deep learning vision inspection platform that addresses the challenges faced by inspectors, enhancing work efficiency. This technology offers capabilities such as power detection, speed detection, and versatility, allowing for greater convenience in development. By automating the inspection process, Saige Research aims to deliver optimal AI solutions that improve quality assurance in manufacturing environments.
Jeongyookgak
Series B in 2020
Jeongyookgak is a company that specializes in the production and sale of fresh meat and groceries. It offers a variety of food items, including pork, beef, eggs, and grass-fed meat, catering to customers seeking high-quality and healthy food options. The company emphasizes rapid delivery services, ensuring that customers receive their orders promptly. By providing online assistance for food delivery, Jeongyookgak aims to meet the growing demand for convenient access to fresh food at reasonable prices.
Toss Payments
Venture Round in 2020
Toss Payments is a developer of an electronic payment management platform designed to facilitate transaction processes for various businesses, including startups and public institutions. The platform offers a range of features such as an account transfer system, virtual accounts, mobile phone micropayments, and billing tools. Additionally, it supports gift voucher payments and automatic transfer services, all aimed at simplifying the flow of transactions. By providing these tools, Toss Payments assists entrepreneurs and franchisees in managing their financial operations more efficiently, reducing settlement cycles and ensuring smooth monetary transactions.
Ubix Therapeutics
Series B in 2020
Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on creating anti-cancer drugs through its innovative proteolysis targeting chimera platform technology. This approach employs inhibitor technology to degrade specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with targeted diseases, Ubix Therapeutics seeks to provide effective and life-saving treatments for patients, thereby supporting medical professionals in their efforts to combat cancer.
Noul
Venture Round in 2020
Noul provides innovative solutions aimed at addressing chronic and systemic healthcare challenges. The company focuses on improving medical access through advanced in vitro diagnostics, contributing to the eradication of both infectious and non-infectious diseases that threaten global health. One of its key offerings is the miLab, an all-in-one, fully automated device capable of processing sample preparation and AI diagnostics in a single workflow. This device integrates technologies from computer vision AI, biology, hardware, and software engineering, positioning Noul as a leader in the development of effective diagnostic solutions.
Healing Paper
Series B in 2020
Healing Paper operates a platform focused on enhancing access to cosmetic surgery services while promoting transparency and affordability. The company utilizes information and communication technology to provide patients with estimates for necessary procedures, honest reviews, and special pricing options. In addition to connecting patients with cosmetic treatment options, Healing Paper fosters a real-time community for sharing experiences and offers management tools for post-surgery care. By balancing information between medical professionals and patients, Healing Paper aims to improve the quality of cosmetic beauty services and make them more accessible.
Musicow
Series B in 2020
Musicow, Inc. is a company based in Seoul, South Korea, that operates an online platform facilitating the investment in music copyrights. Founded in 2017, Musicow allows musical artists to share their copyright with fans, enabling fans to invest in K-Pop songs through a public auction or an online marketplace. The platform offers users the ability to buy and sell fractional ownership of music rights, thereby creating opportunities for fans and investors to earn royalties based on the streaming and usage of the songs. Additionally, Musicow features a secondary marketplace for music copyright trading and project financing, enhancing participation in the music industry and allowing for potential returns on investments.
StyleShare
Series D in 2020
StyleShare Inc. is a South Korean company founded in 2011 that specializes in designing and developing a mobile and web application focused on fashion, beauty, and lifestyle. The platform serves as a real-time space for users to share and receive updates related to these interests, allowing individuals to showcase their daily outfits and recent purchases. With millions of users across 120 countries, StyleShare has established itself as a leading mobile platform in the fashion and beauty sector, earning recognition from prominent publications such as VOGUE, Instyle, and Elle Japan. Through its innovative application, StyleShare facilitates a vibrant community where users can connect over their shared passion for fashion.
AITRICS
Series A in 2020
AITRICS is focused on enhancing patient outcomes through a clinical decision support platform that leverages health data effectively. By utilizing machine learning technologies combined with evidence-based expert analysis, the platform provides real-time clinical insights aimed at transforming traditional reactive disease management into a more proactive, preventive, personalized, and participatory approach to healthcare. This innovative solution is designed to empower clinicians by enhancing treatment strategies and expanding their knowledge, ultimately facilitating better health management for patients. AITRICS comprises a dedicated team of professionals from diverse backgrounds, united by a shared vision to make data-driven health intelligence accessible to all.
StyleShare
Venture Round in 2020
StyleShare Inc. is a South Korean company founded in 2011 that specializes in designing and developing a mobile and web application focused on fashion, beauty, and lifestyle. The platform serves as a real-time space for users to share and receive updates related to these interests, allowing individuals to showcase their daily outfits and recent purchases. With millions of users across 120 countries, StyleShare has established itself as a leading mobile platform in the fashion and beauty sector, earning recognition from prominent publications such as VOGUE, Instyle, and Elle Japan. Through its innovative application, StyleShare facilitates a vibrant community where users can connect over their shared passion for fashion.
OnePredict
Series B in 2019
Established in 2016, OnePredict is a prominent provider of industrial AI technology, recognized for its innovative solutions in machine digitalization and intelligence. The company has won the Global PHM Data Challenge nine times, highlighting its expertise in this field. OnePredict's product line, including the GuardiOne® Series, Cells, Edge, and Cloud solutions, focuses on delivering advanced AI applications for various industrial components such as bearings, turbines, wind farms, transformers, robots, and motors. Its software is designed to transform data into actionable insights through predictive analytics, helping businesses assess the risk of failure and determine the remaining lifespan of critical equipment. By enabling accurate and timely decision-making, OnePredict supports companies across diverse industries in enhancing operational efficiency and reliability.
Supergene
Series B in 2019
Supergene is a social content and game development company based in Pangyo, South Korea, and Manila, Philippines. The company specializes in creating and operating instant games for the Facebook Gaming platform, having launched over 30 titles, including popular games such as Signal, The Puzzle, OMG, OMG AR, Puzzle Wizard, and Super Pop. Notably, OMG achieved significant success as the top game by monthly active users, reaching 300 million in 2020. Supergene focuses on developing engaging puzzle games that allow users to play and share their experiences on social media, enhancing the social gaming landscape.
GF Fermentec
Venture Round in 2019
GF Fermentec is a biotechnology company that specializes in the production of bioactive materials, primarily for the cosmetic industry. The company focuses on developing bioactive biomaterials, with a particular emphasis on ceramide, which is used as a core raw material in skin moisturizing and atopic improvement cosmetic products. Utilizing advanced fermentation technology, GF Fermentec ensures that its raw materials are safe for use in cosmetics, catering to the needs of cosmetic firms seeking high-quality ingredients for their products.
DCGen
Venture Round in 2019
DCGen specializes in the development of a multigene assay kit focused on breast cancer prognosis. This innovative kit analyzes breast cancer-specific somatic mutation genes, aiding in the selection of effective treatment options. By enhancing physicians' understanding and expertise in clinical practice and cancer research, DCGen empowers doctors, patients, and families to make informed medical decisions. Through the application of advanced genomic analysis technologies, the company aims to improve outcomes in breast cancer care.
Aardvark Therapeutics
Series A in 2019
Aardvark Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing and commercializing small molecule therapeutics for obesity and rare genetic metabolic disorders. Founded in 2017 by Tien Lee, the company has introduced Bittera, a first-in-class oral composition designed to selectively disrupt hunger signaling and regulate energy homeostasis. This innovative therapeutic approach provides clinicians with an effective and safe treatment option for obesity-related diseases, without interfering with nutrient absorption. Aardvark Therapeutics aims to address significant health challenges associated with obesity and metabolic conditions through its specialized drug development efforts.
MUSINSA
Venture Round in 2019
MUSINSA is a fashion business company that offers personalized curation and storytelling for various brands and products. Its platform helps brands and consumers' lifestyles by designing, creating, enjoying, and interacting with fashion. It also delivers fashion trends and information to help customers engage and interact.
Woollim Entertainment
Venture Round in 2019
Woollim Entertainment is an entertainment company focused on global cultural content and event management. The company aims to create a new vision for the cultural content industry by leveraging its accumulated knowledge and communication skills in various projects. Woollim Entertainment is dedicated to discovering and nurturing artists capable of succeeding in the global market, while also managing a range of entertainment businesses. Through its comprehensive services, the company enables clients to effectively produce and promote diverse artists, contributing to the broader landscape of the entertainment sector.
Law&Company
Series B in 2019
Law&Company is representative legal tech company in Republic of Korea. The company provides a service called 'LawTalk(www.lawtalk.co.kr)', which is the largest online legal market place in Korea(5 times bigger then the 2nd player). Since 2016, the company invested on research about Artificial Intelligence especially on Text Mining and Machine Learning technology to analyze lawyers and client's activities in the service which helps to lawyers and clients find the right person based on their experience. Also, the company will launch document automation based service to generate legal documents starting from complaint and contract soon. The company has received more than 3 million dollars from 5 venture capital companies and many angel investors due to previous performance and upside potential in the Korean legal market.
Fast Five
Series D in 2019
Fast Five is a premium SOHO office business center designed to provide attractive and efficient co-working spaces for startups and small-to-medium-sized companies. The company operates a membership-based model that allows members to access office spaces in high-demand locations without requiring a deposit. Fast Five aims to foster a sense of community among its members, facilitated by a community manager who helps build connections among founders, investors, professionals, and freelancers. The office environment is enhanced by communal perks such as free coffee, draft beer, and networking events, which promote collaboration and social interaction among members.
Riiid
Series C in 2019
Riiid is a global innovator in AI-powered education solutions, specializing in adaptive assessment platforms that personalize learning experiences for students worldwide. Launched in 2017 with Santa TOEIC, its flagship product has reached over one million users in Korea alone, demonstrating proven efficacy. Expanding globally, Riiid operates Santa TOEIC in Japan and offers Santa SAT in Vietnam. Its scalable AI technology provides each student with a personalized tutor, enhancing learning outcomes while reducing costs compared to traditional methods. By democratizing educational opportunities, Riiid is rapidly transforming the learning landscape.
Blackthorn Therapeutics
Series B in 2019
Blackthorn Therapeutics, based in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurobehavioral disorders. Founded in 2013, the company utilizes a proprietary computational platform that integrates advances in computational and clinical neuroscience to better understand the relationship between brain function and behavior. By targeting dysfunctional brain circuits, Blackthorn aims to address longstanding challenges in drug discovery and development. The company’s approach involves identifying novel therapeutic targets, small molecule drug candidates, and biologically-based patient subgroups that are most likely to benefit from treatment, thereby enhancing the precision of therapeutic interventions in the central nervous system.
Zamong
Series A in 2019
Zamong is a multi-channel network company that focuses on serving one-person media content creators. The company offers a range of services, including creator education developed in collaboration with public institutions and companies, as well as shared studio facilities and creator portal services. Zamong also provides creator management and broadcasting content for both personal and corporate use. This comprehensive support enables clients to produce and share media content with ease, enhancing their creative capabilities and outreach in the digital landscape.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.